DCPH - デシフィラ・ファ―マシュ―ティカルズ (Deciphera Pharmaceuticals Inc.) デシフィラ・ファ―マシュ―ティカルズ

 DCPHのチャート


 DCPHの企業情報

symbol DCPH
会社名 Deciphera Pharmaceuticals Inc (デシフィラ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 デシフェラ・ファーマシューティカルズ(Deciphera Pharmaceuticals Inc.)は臨床段階の製薬会社である。同社はがん患者の生活を改善するための薬物を開発している。同社の薬剤候補には、DCC-2618、DCC-3014およびレバスチニブが含まれる。独自のキナーゼスイッチ制御阻害剤プラットフォームは、キナーゼの活性化を阻害する。DCC-2618はDCC-2618は、消化管間質腫瘍(GIST)、進行性全身性肥満細胞症(ASM)、神経膠芽細胞腫(GBM)およびpan-KITまたはPDGFRアルファによって駆動される他の固形腫瘍の治療用経口投与キナーゼスイッチ制御阻害剤である。DCC-3014は、コロニー刺激因子受容体1(CSF1R)の経口投与された強力かつ高度に選択的な阻害剤である。レバスチニブは、経口的に投与され、TIE2免疫キナーゼの強力で選択的な阻害剤である。レバスチニブは、TIE2のスイッチポケットに強力に結合し、阻害スイッチを安定化させ、活性化スイッチを変位させてTIE2シグナル伝達を遮断する。   デシフィラ・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、がん治療の反応速度を制限する薬剤耐性のメカニズムを研究し、がん患者の生活を改善する新薬の開発に従事する。同社独自のキナ―ゼスイッチ制御阻害プラットフォ―ムによる小分子薬物候補は、多くのがんが転移することを防ぐために開発される。本社所在地はマサチュ―セッツ州ウォルサム。   Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. The Company is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from its platform in clinical studies, QINLOCK is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia.
本社所在地 500 Totten Pond Road Waltham MA 02451 USA
代表者氏名
代表者役職名
電話番号 +1 781-209-6400
設立年月日 42948
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数
url www.deciphera.com
nasdaq_url https://www.nasdaq.com/symbol/dcph
adr_tso
EBITDA EBITDA(百万ドル) -76.68100
終値(lastsale) 30.84
時価総額(marketcap) 1161348078.84
時価総額 時価総額(百万ドル) 1182.06
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 836.92100
当期純利益 当期純利益(百万ドル) -75.07000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Deciphera Pharmaceuticals Inc revenues was not reported. Net loss increased from $18.3M to $43.1M. Higher net loss reflects Research and development increase from $13.8M to $33M (expense) General and administrative increase of 97% to $7.2M (expense) Share-based compensation in Selling Gen increase from $672K to $2.3M (expense).

 DCPHのテクニカル分析


 DCPHのニュース

   Deciphera Announces First Patient Treated in Phase 1 Study of DCC-3116 in Patients with Advanced or Metastatic Tumors with a Mutant RAS or RAF Gene  2021/06/30 20:01:00 Finanzen AT
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced dose administration for the first
   Deciphera Pharmaceuticals (NASDAQ-DCPH) Is In A Good Position To Deliver On Growth Plans  2021/06/24 06:57:17 Yahoo Finance
Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans Yahoo Finance
   Deciphera Pharmaceuticals posts data from cancer studies at ASCO21  2021/06/04 13:47:01 Seeking Alpha
   Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences  2021/05/27 00:00:00 BioSpace
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in fireside chats at the following investor conferences: Jefferies Virtual Healthcare Conference on June 3, 2021 at 1:30 PM ET JMP Securities Life Sciences Conference on June 16, 2021 at 4:00 PM ET
   Deciphera Pharmaceuticals (DCPH) Investor Presentation - Slideshow  2021/05/17 18:50:58 Seeking Alpha
   Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference  2021/03/02 12:00:00 Business Wire
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference on March 9, 2021 at 1:50 PM ET. The conference will be held in a virtual meeting format. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/ne
   Deciphera Pharmaceuticals, Inc. to Present at the SVB Leerink 10th Annual Global Healthcare Conference  2021/02/18 12:00:00 Business Wire
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021 at 4:20 PM ET. The conference will be held in a virtual meeting format. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investo
   Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Corporate Milestones  2021/01/11 12:00:00 Business Wire
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today provided a corporate update and highlighted key 2021 milestones in conjunction with its presentation at the 39th Annual J.P. Morgan Virtual Healthcare Conference. The Company will webcast its presentation today at 9:10 AM ET at https://investors.deciphera.com/news-events/events-presentations
   Deciphera Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference  2021/01/05 12:23:00 Business Wire
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 9:10 AM ET. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/news-events/events-presentations. A replay of the webcast will b
   Medison Pharma beschließt regionsübergreifende Vertriebspartnerschaft mit Deciphera Pharmaceuticals zur Vermarktung von QINLOCK® (Ripretinib)  2020/11/06 19:15:00 PR Newswire
PETACH TIKVA, Israel und WALTHAM, Massachusetts, 6. November 2020 /PRNewswire/ -- Medison Pharma ist ein weltweit führender Handelspartner für hochmoderne Therapien. Das Unternehmen hat heute seine exklusive Vertriebspartnerschaft mit Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)…
   Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference  2021/03/02 12:00:00 Business Wire
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference on March 9, 2021 at 1:50 PM ET. The conference will be held in a virtual meeting format. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/ne
   Deciphera Pharmaceuticals, Inc. to Present at the SVB Leerink 10th Annual Global Healthcare Conference  2021/02/18 12:00:00 Business Wire
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021 at 4:20 PM ET. The conference will be held in a virtual meeting format. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investo
   Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Corporate Milestones  2021/01/11 12:00:00 Business Wire
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today provided a corporate update and highlighted key 2021 milestones in conjunction with its presentation at the 39th Annual J.P. Morgan Virtual Healthcare Conference. The Company will webcast its presentation today at 9:10 AM ET at https://investors.deciphera.com/news-events/events-presentations
   Deciphera Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference  2021/01/05 12:23:00 Business Wire
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 9:10 AM ET. A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/news-events/events-presentations. A replay of the webcast will b
   Medison Pharma beschließt regionsübergreifende Vertriebspartnerschaft mit Deciphera Pharmaceuticals zur Vermarktung von QINLOCK® (Ripretinib)  2020/11/06 19:15:00 PR Newswire
PETACH TIKVA, Israel und WALTHAM, Massachusetts, 6. November 2020 /PRNewswire/ -- Medison Pharma ist ein weltweit führender Handelspartner für hochmoderne Therapien. Das Unternehmen hat heute seine exklusive Vertriebspartnerschaft mit Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 デシフィラ・ファ―マシュ―ティカルズ DCPH Deciphera Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)